The efficacy of temozolomide for recurrent glioblastoma multiforme

The efficacy of temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM) has been evaluated by several clinical trials. A meta‐analysis to assess the overall efficacy of TMZ in the treatment of recurrent GBM was carried out by the authors.

[1]  R. Mirimanoff,et al.  Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Tolcher,et al.  Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.

[3]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[4]  H. Kurzen,et al.  Inhibition of angiogenesis by non-toxic doses of temozolomide , 2003, Anti-cancer drugs.

[5]  M. Rosenthal,et al.  Phase II study of two-weekly temozolomide in patients with high-grade gliomas , 2006, Journal of Clinical Neuroscience.

[6]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[7]  N. Bleehen,et al.  Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma , 1997, Cancer Chemotherapy and Pharmacology.

[8]  W. Poon,et al.  Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. , 2005, Hong Kong medical journal = Xianggang yi xue za zhi.

[9]  J. Ioannidis,et al.  Quantitative Synthesis in Systematic Reviews , 1997, Annals of Internal Medicine.

[10]  J. Dichgans,et al.  One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.

[11]  A. Brandes,et al.  Temozolomide in Patients with Glioblastoma at Second Relapse after First Line Nitrosourea-Procarbazine Failure: A Phase II Study , 2002, Oncology.

[12]  S. Gautam,et al.  Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  C. Belka,et al.  Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide , 1999, Journal of Cancer Research and Clinical Oncology.

[14]  Jung-Il Lee,et al.  Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. , 2010, Neuro-oncology.

[15]  M. J. van den Bent,et al.  Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  G. Reifenberger,et al.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Brandes,et al.  Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) , 2006, British Journal of Cancer.

[18]  M. Rosenthal,et al.  An Australian experience with temozolomide for the treatment of recurrent high grade gliomas , 2001, Journal of Clinical Neuroscience.

[19]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Balañà,et al.  Extended-schedule dose-dense temozolomide in refractory gliomas , 2009, Journal of Neuro-Oncology.

[22]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[23]  J. Menten,et al.  A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma , 2008, Cancer investigation.

[24]  O. Chinot,et al.  Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Gasparini,et al.  Metronomic scheduling: the future of chemotherapy? , 2001, The Lancet. Oncology.

[26]  D. Osoba,et al.  Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[29]  Jung-Il Lee,et al.  A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. , 2006, Oncology reports.

[30]  U. Abacıoğlu,et al.  Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma , 2011, Journal of Neuro-Oncology.

[31]  K. Hopkins,et al.  Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[33]  J. Raizer,et al.  A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. , 2002, Neuro-oncology.

[34]  S. Pannullo,et al.  Multi‐institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high‐grade gliomas , 2008, Cancer.

[35]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Susan M. Chang,et al.  Temozolomide in the treatment of recurrent malignant glioma , 2004, Cancer.

[37]  D. Crowther,et al.  Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. , 1994, British Journal of Cancer.

[38]  J. Pichler,et al.  Temozolomide for recurrent or progressive high-grade malignant glioma: Results of an Austrian multicenter observational study , 2006, Wiener klinische Wochenschrift.

[39]  D. Osoba,et al.  Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. , 2000, European journal of cancer.

[40]  M. Christmann,et al.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.

[41]  E. Newlands,et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.

[42]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Yang,et al.  Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas , 2006, Journal of Korean medical science.

[44]  K. Plate,et al.  Angiogenesis in malignant gliomas , 1995, Glia.

[45]  G. Aravantinos,et al.  Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status , 2000, Medical oncology.

[46]  K. Sugiyama,et al.  A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme , 2003, International Journal of Clinical Oncology.

[47]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S P Langdon,et al.  Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.

[49]  M Brada,et al.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  A. Brandes,et al.  Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. , 2001, Annals of Oncology.

[51]  M. Caroli,et al.  Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? , 2007, Journal of Neuro-Oncology.

[52]  A. Pegg.  Repair of O6-alkylguanine by alkyltransferases , 2000 .

[53]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.